ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
SeaStar Medical Holding Corporation

SeaStar Medical Holding Corporation (ICU)

0.6626
0.00
(0.00%)
Closed April 16 4:00PM
0.00
0.00
(0.00%)

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
0.6626
Bid
0.6511
Ask
0.669
Volume
-
0.00 Day's Range 0.00
0.162 52 Week Range 2.50
Market Cap
Previous Close
0.6626
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
5,954,996
Shares Outstanding
36,979,724
Dividend Yield
-
PE Ratio
-1.06
Earnings Per Share (EPS)
-0.62
Revenue
-
Net Profit
-23.01M

About SeaStar Medical Holding Corporation

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs.

Sector
Surgical,med Instr,apparatus
Industry
Blank Checks
Headquarters
Wilmington, Delaware, USA
Founded
2022
SeaStar Medical Holding Corporation is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker ICU. The last closing price for SeaStar Medical was $0.66. Over the last year, SeaStar Medical shares have traded in a share price range of $ 0.162 to $ 2.50.

SeaStar Medical currently has 36,979,724 shares outstanding. The market capitalization of SeaStar Medical is $24.41 million. SeaStar Medical has a price to earnings ratio (PE ratio) of -1.06.

ICU Latest News

SeaStar Medical to Present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference

DENVER, April 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the...

SeaStar Medical to Restate Financials, Sets Business Update Call for April 17

Restatement of non-cash items is not expected to materially impact cash position or operations DENVER, March 27, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a...

SeaStar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients

Company plans to hold a business update conference call in April DENVER, March 12, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial stage medical device...

SeaStar Medical-Sponsored Symposium Featuring Experts Discussing Pediatric Acute Kidney Injury and the Selective Cytopheretic Device to be Webcast Live at AKI & CRRT 2024

March 13 webcast showcasing Quelimmune™ scientific background and clinical data for pediatric AKI due to sepsis or a septic condition will be available on seastarmedical.com DENVER, March 11...

Manuscript Discussing the Benefit of SeaStar Medical’s Selective Cytopheretic Device in Patients with Heart Failure and Hyperinflammation Published in European Journal of Heart Failure

Interest continues to grow in developing new strategies to reduce systemic inflammation as a means of improving outcomes in heart failure patients DENVER, Feb. 27, 2024 (GLOBE NEWSWIRE...

Nuwellis’ Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune™

MINNEAPOLIS, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced its...

FDA Grants Humanitarian Device Exemption Approval to SeaStar Medical’s Selective Cytopheretic Device for Pediatric Acute Kidney Injury

SCD-PED (Pediatric) is the first FDA-approved product in the Company’s Quelimmune™ product family DENVER, Feb. 22, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a...

SeaStar Medical Granted Canadian Patent with Broad Claims Covering the Selective Cytopheretic Device Technology

DENVER, Feb. 01, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.00240.3635262041810.66020.80.60201617222100.68058517CS
4-0.1764-21.02502979740.8390.8797990.60201617738390.73289025CS
12-0.0424-6.014184397160.7051.71690.5499559549960.90387907CS
260.161632.2554890220.5011.71690.3682250420.87224491CS
52-1.4874-69.18139534882.152.50.16260994790.75040475CS
156-10.5674-94.099732858411.2312.20.16242613640.82814117CS
260-10.5674-94.099732858411.2312.20.16242613640.82814117CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AAGRAfrican Agriculture Holdings Inc
$ 0.4174
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 60.04
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.90
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 11.2801
(0.00%)
0
AACGATA Creativity Global
$ 0.86
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.4174
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 60.04
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.90
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 11.2801
(0.00%)
0
AACGATA Creativity Global
$ 0.86
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.4174
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 60.04
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.90
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 11.2801
(0.00%)
0
AACGATA Creativity Global
$ 0.86
(0.00%)
0

ICU Discussion

View Posts
theswordman theswordman 1 week ago
CONF CALL REGISTRATION--The link is now live on webpage.
https://dpregister.com/DiamondPassRegistration/register?confirmationNumber=10187590&linkSecurityString=fc04ba1430

17 APR--WED @ 4 PM Eastern
👍️0
theswordman theswordman 2 weeks ago
kidney disease prevalence is increasing globally and it is now the seventh leading risk factor for mortality worldwide

https://www.nature.com/articles/s41581-024-00820-6

Failure to include kidney disease in this initiative misses the opportunity to address a major contributor to premature and preventable mortality.
👍️0
theswordman theswordman 3 weeks ago
SeaStar and SCD getting a shoutout TODAY in Extracorporeal Organ Support for Burn-Injured Patients issue of Medical Sciences by MDPI.

5.3. Cell-Directed Extracorporeal Therapy
The Selective Cytopheretic Device (SCD) (SeaStar Medical, Denver, CO, USA), is a technology that sequesters and modulates the most activated neutrophils and monocytes . The SCD is a biocompatible membrane that mimics capillary blood flow and sequesters activated leukocytes. The SCD is utilized in conjunction with CKRT, with the SCD downstream from the CKRT hemofilter in the circuit. The SCD requires the use of regional citrate anticoagulation to induce hypocalcemia within the SCD, which results in both the inhibition of the clotting cascade but also the inactivation of leukocytes. There are a number of smaller studies in critically ill medical patients which have shown promising results, but there are limited data including burn patients . A multicenter randomized controlled trial, NEUTRALIZE-AKI, is currently enrolling critically ill patients with AKI, who require CKRT .

https://www.mdpi.com/2673-1991/5/2/6
👍️0
theswordman theswordman 4 weeks ago
The AKI & CRRT 2024 (San Diego)--that webinar is NOW uploaded to SeaStar website for replay. It does include the Q & A portion also. Great info in this. Good questions.
https://s201.q4cdn.com/298572669/files/images/introducing_quelimmune__new_approved_therapy_for_pediatric_aki_due_to_sepsis-720p.mp4
👍️0
theswordman theswordman 4 weeks ago
C K D Summit--Dr Chung presentation--20 MAR/Boston

https://ckd3-summit.com/seminar/session-reserved-seastar-medical/
👍️0
theswordman theswordman 1 month ago
Dr Chung is presenting today (16 MAR) @ KDCT Conference (Kidney Disease Clinical Trialists)

The schedule/topics are linked here
https://www.kdctmeeting.com/scientific-program

It is the 3pm slot. Notice ALSO the 1 moderator (Sean Bagshaw)--ring a bell??
Session 9--Developing Core Outcome Sets In AKI Trials
👍️0
abrooklyn abrooklyn 1 month ago
SeaStar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients

Source: GlobeNewswire Inc.

SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, provides updates on the acute kidney injury (AKI) programs it is developing with its patented, first-to-market, cell-directed Selective Cytopheretic Device (SCD) extracorporeal therapy in critically ill patients with AKI.
“We now have 21 subjects enrolled across five clinical sites in our NEUTRALIZE-AKI pivotal clinical trial, which is intended to evaluate the safety and efficacy of our SCD in adult AKI patients. Additional sites are progressing through the site activation and contract completion process,” said Kevin Chung, MD, Chief Medical Officer of SeaStar Medical. “We expect the pace of enrollment will accelerate as more medical centers come onboard. We anticipate conducting an interim analysis once we have reached our 90-day primary endpoint in 100 enrolled subjects, which we expect to reach in the second half of 2024.”

The NEUTRALIZE-AKI (NEUTRophil and monocyte deActivation via SeLective Cytopheretic Device – a randomiZEd clinical trial in Acute Kidney Injury) pivotal trial is expected to enroll up to 200 adults. The trial’s primary endpoint is a composite of 90-day mortality or dialysis dependency of patients treated with SCD in addition to continuous kidney replacement therapy (CKRT) as the standard of care, compared with the control group receiving only CKRT standard of care. Secondary endpoints include mortality at 28 days, ICU-free days in the first 28 days, major adverse kidney events at Day 90 and dialysis dependency at one year. The study will also include subgroup analyses to explore the effectiveness of SCD therapy in AKI patients with sepsis and acute respiratory distress syndrome. More information on the trial is available here.

In February 2024 the U.S. Food and Drug Administration (FDA) granted a Humanitarian Device Exemption (HDE) Approval Order to the Quelimmune™ pediatric device for use in children weighing 10 kilograms or more with AKI due to sepsis or a septic condition requiring kidney replacement therapy (KRT).

“Interactions with several key target hospitals are underway with plans to expand the commercial rollout with Nuwellis, Inc. during the second quarter,” said Eric Schlorff, CEO of SeaStar Medical. “As our therapeutic device is approved under an HDE, each hospital is required to secure institutional review board approval prior to purchasing the device for use in patients. We view Quelimmune as a tremendous win for children with AKI requiring CKRT given clinical results from our AKI pediatric trials that showed a 77% survival rate and no dialysis dependency at 60 days in those subjects, as well as for the healthcare system given the average cost of dialysis for a single patient with AKI who develops chronic kidney disease is about $100,000 annually.”

SeaStar Medical estimates the eligible population for its Quelimmune pediatric device to be approximately 4,000 children annually with AKI. About 20% of the top 50 children’s hospitals already have direct experience with the SCD. Pediatric patients undergoing treatment with the SCD are expected to require, on average, seven SCD units, with the disposable device being changed once every 24 hours. With the Approval Order, SeaStar Medical can build Quelimmune Clinical Kits into inventory in parallel to the hospital approvals process.

The FDA’s HDE Approval Order was based on a pooled analysis from two non-controlled studies, SCD-PED-01 (funded by the FDA Office of Orphan Products Development) and SCD-PED-02. These studies showed that pediatric patients weighing ≥10kg with AKI requiring CKRT treated with the Quelimmune pediatric device had no device-related serious adverse events or device-related infections, a 77% survival rate, and no dialysis dependency at Day 60. The SCD-PED-01 (weight range ≥15 kg) and SCD-PED-02 (weight range ≥10 kg) studies demonstrated 75% and 83% survival rates, respectively.

SeaStar Medical also announces that its executive management team plans to hold a business update conference call in April to discuss progress with its AKI programs and opportunities in other indications, and to answer questions. Details regarding this call will be made available in the coming weeks.

About Hyperinflammation
Hyperinflammation is the overproduction or overactivity of inflammatory cells that can lead to damage of vital organs. It occurs when the body overproduces inflammatory effector cells and other molecules that can be toxic, damaging to vital organs and result in multi-organ failure and even death. This is known as the cytokine storm.

About The Selective Cytopheretic Device
The Selective Cytopheretic Device (SCD) is a patented cell-directed extracorporeal device that employs immunomodulating technology to selectively target proinflammatory neutrophils and monocytes during CKRT and reduces the hyperinflammatory milieu including the cytokine storm that causes inflammation, organ failure and possible death in critically ill patients. Unlike pathogen removal and other blood-purification tools, the SCD is integrated with CKRT hemofiltration systems to selectively target and transition proinflammatory monocytes to a reparative state and promote activated neutrophils to be less inflammatory. The SCD selectively targets the most highly activated proinflammatory neutrophils and monocytes. These cells are then returned back into the body through the blood, and the body is signaled to lower its inflammatory environment and focus on repair. This unique immunomodulation approach may promote long-term organ recovery and eliminate the need for future KRT, including dialysis. Quelimmune is the official brand name for the Selective Cytopheretic Device in pediatrics that has received FDA HDE Approval based on safety and probable efficacy.

About SeaStar Medical
SeaStar Medical is a commercial-stage, medical technology company that is redefining how extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs. SeaStar Medical’s novel technologies rely on science and innovation to provide life-saving solutions to critically ill patients. The Company is developing and commercializing cell-directed extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. For more information visit www.seastarmedical.com or visit us on LinkedIn or X.

Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1955. These forward-looking statements include, without limitation, the SCD’s ability to treat hyperinflammation and the expected results of clinical trials and studies. Words such as “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside SeaStar Medical’s control and are difficult to predict. Factors that may cause actual future events to differ materially from the expected results include, but are not limited to: (i) the risk that SeaStar Medical may not be able to obtain regulatory approval of its SCD product candidates; (ii) the risk that SeaStar Medical may not be able to raise sufficient capital to fund its operations, including clinical trials; (iii) the risk that SeaStar Medical and its current and future collaborators are unable to successfully develop and commercialize its products or services, or experience significant delays in doing so, including failure to achieve approval of its products by applicable federal and state regulators, (iv) the risk that SeaStar Medical may never achieve or sustain profitability; (v) the risk that SeaStar Medical may not be able to access funding under existing agreements, including the equity line of credit and forward purchase agreements; (vi) the risk that third-parties suppliers and manufacturers are not able to fully and timely meet their obligations, (vii) the risk of product liability or regulatory lawsuits or proceedings relating to SeaStar Medical’s products and services, (viii) the risk that SeaStar Medical is unable to secure or protect its intellectual property, and (ix) other risks and uncertainties indicated from time to time in SeaStar Medical’s Annual Report on Form 10-K, including those under the “Risk Factors” section therein and in SeaStar Medical’s other filings with the SEC. The foregoing list of factors is not exhaustive. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SeaStar Medical assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact:

LHA Investor Relations
Jody Cain
(310) 691-7100
Jcain@lhai.com

# # #



Primary Logo
👍️0
theswordman theswordman 1 month ago
SeaStar gets a shoutout in article

https://www.renalandurologynews.com/news/nephrology/acute-kidney-injury/more-severe-aki-predicts-adverse-outcomes-in-critically-ill-children/
👍️0
theswordman theswordman 1 month ago
Dr Batchinsky is a member of SAB. U.S. Army connections--along with CMO Dr Chung.This is something he is progressing: https://genevausa.org/news/story/geneva-scientist-invents-wearable-life-support-to-change-critical-care/
👍️0
theswordman theswordman 1 month ago
within 12 hours her course progressed to multiple organ failure, including anuric AKI, shock liver, respiratory failure, and refractory shock.

Our institution also requested the emergency use of an investigational extracorporeal device known as the SCD from SeaStar Medical.

https://journals.lww.com/ccejournal/fulltext/2024/03000/sequential_extracorporeal_therapy_of_pathogen.2.aspx
👍️0
harry crumb harry crumb 1 month ago
Now what, exited position last week on the pump, thank the stock gods, lol. So the news was sold and shorts are dominating now but seems decent support around this area
👍️0
theswordman theswordman 2 months ago
UPDATED--Looks NICE!!!
👍️ 1
frans frans 2 months ago
ICU up up now 0.8945
👍️ 1
macnai macnai 2 months ago
SeaStar will bob back up again after being raided by Pirates.
Big investors ie. institutions set off a selling panic among short-term investors by selling short and were able to buy back in bulk yesterday at much-reduced prices. They see the great future of this company and want to be in with decent size stakes.
My view ......take it or leave it.
👍️0
frans frans 2 months ago
that is NOT normal trading here now my 0.76
👍️0
frans frans 2 months ago
yes
👍️0
TheFinalCD TheFinalCD 2 months ago
stock market is full of surprises

many of which arent good
👍️0
frans frans 2 months ago
now 0.71 better bought it at 0.76
👍️0
TheFinalCD TheFinalCD 2 months ago
$ICU .52 what in TARNATION
👍️0
frans frans 2 months ago
what is going on here after FDA news ???
👍️0
theswordman theswordman 2 months ago
FDA APPROVAL LETTER
https://www.fda.gov/media/176511/download
👍️0
macnai macnai 2 months ago
Sellers pre-market will be weeping later today.
Hold and buy more if you can.
👍️0
Tom turtles Tom turtles 2 months ago
Wow....can you imagine when this has bad news ? FDA Approved and the stock plummets like a free falling boulder. In the .70's now pre-market. These criminals should be investigated. Didn't buy into any of the hype. Feel sorry though, for investors that did.
👍️0
theswordman theswordman 2 months ago
A Beacon of Hope

This isn't just a step forward in healthcare - it's a giant leap in the battle against a condition that has long challenged the pediatric intensive care community.
the Quelimmune device is set to become a standard of care for AKI in the ICU
hopeful for the impact this device will have on critically ill children with few treatment options

https://bnnbreaking.com/breaking-news/health/a-beacon-of-hope-fda-approves-innovative-device-for-pediatric-kidney-injury
👍️ 1
macnai macnai 2 months ago
Now is the TIME TO BUY
👍️0
macnai macnai 2 months ago
Today or tomorrow.
I would expect management to tell us how they will develop the business.
Expect a relentless rise in the stock price starting today.
👍️0
macnai macnai 2 months ago
FDA Grants Humanitarian Device Exemption Approval to SeaStar Medical’s Selective Cytopheretic Device for Pediatric Acute Kidney Injury
February 22, 2024
SCD-PED (Pediatric) is the first FDA-approved product in the Company’s Quelimmune™ product family

DENVER, Feb. 22, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that the U.S. Food and Drug Administration (FDA) has granted a Humanitarian Device Exemption (HDE) Approval Order to the Selective Cytopheretic Device (SCD) Pediatric (SCD-PED) for use in children weighing 10 kilograms or more with acute kidney injury (AKI) due to sepsis or a septic condition requiring kidney replacement therapy (KRT). This is the first product in the Company’s newly branded Quelimmune product family, and the Quelimmune pediatric device can now be commercially marketed as a Humanitarian Use Device (HUD).

“This first regulatory approval is a major accomplishment for our company and, most importantly, it provides critically ill children with AKI access to a much-needed new therapy,” said Eric Schlorff, SeaStar Medical CEO. “Only about one-half of the children in the ICU with AKI requiring CKRT survive, and those who do are at increased risk of long-term conditions such as chronic kidney disease. In clinical studies, Quelimmune for pediatric AKI has been shown to reduce mortality rates and dialysis dependency in clinical studies.

“We appreciate the FDA’s willingness to work collaboratively with SeaStar Medical and our advisors to grant HDE approval to Quelimmune for pediatric use,” Mr. Schlorff added. “We believe the HDE for children weighing as little as 10 kilograms – or roughly 22 pounds – acknowledges the proven life-saving capabilities of our device and addresses a critical unmet need for patients. We are working to make Quelimmune therapy the new standard of care for AKI requiring CKRT in the ICU and to demonstrate its benefit in the many indications where hyperinflammation and dysregulated inflammatory processes are involved.”

The initial commercial launch of Quelimmune for pediatric AKI is expected in the coming weeks by SeaStar Medical’s U.S. license and distribution partner Nuwellis, with a full commercial program to follow. Nuwellis has established strong relationships with pediatric nephrology and intensive care key opinion leaders across the U.S.

“The unique technology behind Quelimmune has demonstrated great promise in making a positive impact on children with potentially deadly hyperinflammation,” said Nestor Jaramillo, Jr., Nuwellis President and CEO. “The pediatric segment of our business has gained significant traction over the past several years, and we are excited to add the Quelimmune pediatric device to our product offering.”

The FDA granted HDE approval to the Quelimmune pediatric device for AKI based upon clinical results showing safety and probable clinical benefit to critically ill children with AKI who have few treatment options. Pooled analysis from two non-controlled studies, SCD-PED-01 (funded by the FDA Office of Orphan Products Development) and SCD-PED-02 showed that pediatric patients ≥10kg with AKI requiring CKRT treated with the Quelimmune pediatric device had no device-related serious adverse events or device-related infections, a 77% reduction in mortality rate, and no dialysis dependency at Day 60. The SCD-PED-01 (weight range ≥15 kg) and PED-02 (weight range ≥10 kg) studies demonstrated 75% and 83% reductions in mortality, respectively. These data were recently published in the journal Kidney Medicine. SeaStar Medical is currently focused on its NEUTRALIZE-AKI pivotal clinical trial to evaluate Quelimmune therapy in the larger adult AKI population, while exploring other applications for this device.
👍️0
macnai macnai 2 months ago
BIG NEWS TODAY
Forget the Moon....this is going Interstellar.
See also this recent report

kidneymedicinejournal.org/a...
"As with recent advances in neonatal CRRT technology, work is underway to develop a miniaturized version of the SCD to address the needs of the population less than 10 kg in size."
👍️0
MJAM2020 MJAM2020 2 months ago
Nice nice... .029 here still havent sold one unit.


Imho
👍️ 1 😁 1
weedtrader420 weedtrader420 2 months ago
ICUCW WOOHOOOOOOOOOOOOOOOOOOOOOOO started buying under $0.02 no competition 🤣😂🤣😂
👍️0
theswordman theswordman 2 months ago
Why Medicare/Medicaid will ALSO want the FDA to "assist" in getting approval
Won't just be BCBS or for profit health ins corps looking at "expenses" at "how can we cut costs and maintain patient care"

https://strivehealth.com/news/patients-vs-profits-who-wins-in-the-traditional-u-s-dialysis-system/#:~:text=The%20cost%20of%20dialysis%20is,goes%20toward%20paying%20for%20dialysis.
👍️0
tw0122 tw0122 2 months ago
Series A warrants and Series B warrants is $0.8302. The Series A warrants will have an exercise price of $0.8302 per share, expire five years from the date of stockholder approval, and will become exercisable upon the date of stockholder approval. The Series B warrants will have an exercise price of $0.8302 per share, expire one year from the date of stockholder approval, and will become exercisable upon the date of stockholder approval. The Company expects to receive gross proceeds in the amount of approximately $9.0 million from the offering.
Maxim Group LLC is acting as the sole placement agent for the offering.

The offering is expected to close on or about January 30, 2024, subject to the satisfaction of customary closing conditions.
👍️0
Klinsmann Klinsmann 2 months ago
Jep, early PR tom. could make this the „stock of the week“
👍️0
da_stock_analyst da_stock_analyst 2 months ago
#ICU 🔥 catalyst coming! $2+ this week? $ICU
👍️0
harry crumb harry crumb 2 months ago
Peeps let something out to be announced, could be an epic pop come premarket monday
👍️0
SwanSong99 SwanSong99 2 months ago
Some things are worth waiting for, ICU!!
The next week will be interesting
👍️0
theswordman theswordman 2 months ago
Don't really understand "after hours" and why the jump after hours--but a impressive run regardless. Looking over at info/graph to the right--big confirmation.--------------------->>>------>>>>>>>>>>>>>>>>>>^^^^^^^^^^^^^^
👍️0
MJAM2020 MJAM2020 2 months ago
Wake up folks..it looks like its time :) Broke out on the chart after hrs.

imho
mj
👍️0
kbaz kbaz 2 months ago
Getting Ducks in a Row for a Commercialization Ramp Up!!!! $2 to $3 before you know it!!!
👍️0
Klinsmann Klinsmann 3 months ago
This chart is primed for breakout! Plus pr about closed offering should come out today...
👍️0
Beauneedsbiscuits Beauneedsbiscuits 3 months ago
Ya you like those that loose 99% You just can't stand to admit it
👍️0
kbaz kbaz 3 months ago
I like it!!!! gives me my kicks!!!!! But Im not a sucka that pushed way too much money and down over 95% in a SCAM!!!!
👍️0
Beauneedsbiscuits Beauneedsbiscuits 3 months ago
Maybe you should ask the couple that's still post here? Would you continue posting on an OTC stock that you supposedly sold 3 years ago ?Especially after being goaded into responding because everybody knows you have severe OCD and can't rexist posting dribble. Add to that the whole list of failed stocks promoted since COVID market binge was over. And even though they knock An OTC stock that has been beaten down with the rest of the OTC market, yet Still shows being profitable.. They try to sell the idea that a failed MMA promoter with huge debt and very little revenue... Is a better investment bet? So who here besides Kbaz Would continue posting on a site practically every day 2 or 3 times on a stock they supposedly sold 3 years ago? Anybody? 1 person. BTW, all he has to do is move on and he'd stop hearing from his "admirers"....baahhaaaaa.
👍️0
kbaz kbaz 3 months ago
It was a 1...2 setup on News.... The First announcement was to Soften the Pricing and the 2nd was Solid as Hell! As ICU got validated from the JPM Week! We gonna see how Strong the Shorts were vs the Weak Hands.... When that battle done we movin' on up.... Interesting on a Friday Too!!!!!! One more News to see would be a Commercial Contract with Some Healthcare (Hospital) Companies!!!

👍️0
Klinsmann Klinsmann 3 months ago
Has been priced in and this is not new as it was known before. And it gonna get eaten up quickly imo. This story is just getting started!
👍️0
kbaz kbaz 3 months ago
Weak hand Flush out.... Leaving the WEAK Behind.... Let it Play Out!!!! We partnered up with a JPM Playa!!!!!!! And now loaded with Cash to Spend for some Big Returns!!!!!
👍️0
kbaz kbaz 3 months ago
That's private placement from the JPM week. HELL YEAH got some more!!!!!

Weak Hand Flush Out!!!!! EXCELLENT DAY!!!!!!!
👍️0
kbaz kbaz 3 months ago
His DD is reading what the Grifter Puts on Social Media..... He Can't Read Fin's (primarily Cash Flows) and he Still takes the JAB and Wears a Mask, Because O'Biden tells him to..... Kinda Sad Actually!!!!! People shouldn't follow his (BeauneedsBizkits) Advice!!!! He'd mandate you to buy that POS filipino Scam if he Could!!!!!!
👍️0
harry crumb harry crumb 3 months ago
Probably hit the 2$ chart on next big news, an news could be sooner than most think here. Patience brings wealth but greed brings the color red, pick an choose your entry an exit $$$$$$
👍️0
harry crumb harry crumb 3 months ago
We’ll take a flip on this any day, .55 average to .80’s any day on 45k shares is money made easy $$$$$$
👍️0

Your Recent History

Delayed Upgrade Clock